首页> 外文期刊>Journal of Clinical and Diagnostic Research >Interlinking Periodontitis and Type 2 Diabetes Mellitus by Assessment of Crevicular Visfatin Levels in Health and in Disease Before and After Initial Periodontal Therapy
【24h】

Interlinking Periodontitis and Type 2 Diabetes Mellitus by Assessment of Crevicular Visfatin Levels in Health and in Disease Before and After Initial Periodontal Therapy

机译:通过评估牙周Visfatin水平在健康和疾病中的牙周炎和2型糖尿病之间的关系,这些牙周炎在初次牙周治疗之前和之后

获取原文
获取外文期刊封面目录资料

摘要

Introduction: Visfatin is a new adipocytokine associated with both chronic periodontitis and type 2 diabetes mellitus independently. Aim: We aimed to estimate and compare the changes in the levels of visfatin in the Gingival Crevicular Fluid (GCF) of healthy subjects and in subjects with periodontitis with or without controlled Type 2 Diabetes Mellitus (T2DM) after administration of non-surgical periodontal therapy. Materials and Methods: Forty two subjects were equally divided into Group 1 (healthy), Group 2 (systemically healthy with chronic periodontitis), Group 3 (subjects with chronic periodontitis having controlled T2DM). Defined clinical parameters were recorded at baseline and at one month follow-up period. Visfatin was assessed using enzyme linked immunosorbent assay. One way ANOVA and Tukey?s multiple post hoc procedures were used. Pearson?s correlation coefficient was used for correlation. Results: Significant increase in the visfatin levels was seen with the highest values observed in diabetes with periodontal disease. Visfatin responded to non-surgical periodontal therapy as observed by significant decrease in levels after one month but even at this period diabetics showed the highest levels. Conclusion: Visfatin levels are highest in individuals with both periodontal disease and diabetes even after periodontal therapy. Individuals with T2DM may be at higher risk of developing periodontal disease.
机译:简介:Visfatin是一种新的脂肪细胞因子,与慢性牙周炎和2型糖尿病无关。目的:我们旨在评估和比较健康受试者和非控制性2型糖尿病(T2DM)患牙周炎患者健康受试者牙龈沟液(GCF)中的visfatin水平变化。材料和方法:42位受试者被平均分为第1组(健康),第2组(全身健康且患有慢性牙周炎),第3组(患有慢性牙周炎且控制了T2DM的受试者)。在基线和一个月的随访期记录定义的临床参数。使用酶联免疫吸附测定法评估Visfatin。一种方法是使用ANOVA和Tukey的多个事后程序。皮尔逊相关系数用于相关。结果:在患有牙周疾病的糖尿病患者中,观察到的visfatin水平明显升高。 Visfatin对非手术性牙周治疗有反应,一个月后血浆水平明显下降,但即使在这一时期,糖尿病患者仍显示最高水平。结论:即使在牙周治疗后,Visfatin水平在牙周疾病和糖尿病患者中最高。患有T2DM的个体患牙周疾病的风险可能更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号